ClinicalTrials.gg

Program

BWC0977

A development code.

Its studies are mostly in Communicable Diseases, led by Bugworks Research.

Furthest: phase 1, since Sep 9, 20213 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bugworks Research31 open or runningphase 1since Sep 9, 2021Sep 9, 2021Jun 30, 2027phase 1 · NCT07029932

Also a collaborator on its studies: avance-clinical-pty-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2021First study: phase 1 study in Communicable DiseasesFirst studyNCT05088421 · 44 enrolled · Australia
  2. Jul 5, 2023Phase 1 study in Communicable DiseasesNCT05942820 · 4 enrolled · Australia
  3. Jun 12, 2025Phase 1 study in Communicable DiseasesNCT07029932 · 48 planned · Australia

Ahead

  1. Jun 30, 2027Primary completion: phase 1 study in Communicable DiseasesNCT07029932

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07029932Communicable Diseases · Australia1RecruitingJun 30, 202748
NCT05942820Communicable Diseases · Australia1TerminatedJan 30, 20244
NCT05088421Communicable Diseases · Australia1CompletedDec 29, 202244

How it is read

Names in the registry

  • “BWC0977”, 3 entries

Codes read as this program: BWC0977.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.